Mongodb Inc vs Twist Bioscience Corp — how do they compare? Mongodb Inc trades at $307.85 (market cap $26.01B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Mongodb Inc is far larger — about 4.8× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Mongodb Inc nearer its low. Which is the better fit depends on your goals.
| MDB | TWST | |
|---|---|---|
Market Cap | $26.01B | $5.45B |
Sector | Technology | Health |
52-Week High | $440.25 | $102.88 |
52-Week Low | $201.08 | $24.16 |
Enterprise Value | $23.61B | $5.37B |
Signals from Pluang's Aura AI — not financial advice
MDB trades at $307.65, down 1.5% today, with a bearish technical signal despite recent earnings beats. Revenue growth is strong at $2.01B for 2025, but the company remains unprofitable with a net margin of -1.12%. Analyst sentiment is overwhelmingly positive with an 81.81% buy rating and a $400.39 consensus price target, though negative cash flow and high valuation multiples present challenges.
The outlook hinges on MDB's ability to sustain revenue momentum and achieve profitability. Investment opportunity lies in its leadership in database solutions and AI-driven demand growth. Key risks include persistent cash burn, competitive pressures, and high valuation metrics that may not justify current losses if growth slows.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →